1.Proprietary DPNP  deliver siRNA  for HBV therapeutics which may cure hepatitis B functionally.

2.DPNP delivery technology can be used to develop a variety of RNAi therapeutics.

3.A team with knowledge and skill in RNAi drug development team.

4.Multi-Valent Import Platform(MVIP) can directly modify the old molecules with severe  side effects or adverse effects to other tissues in the clinical use and greatly shorten the pre-clinical development cycle.

5.Lipid-Coupling Delivery Platform(LCDP) directly inserts the compound at the end or middle of the siRNA to enhance the siRNA backbone structure, and can be used for topical application in drug development of various solid tumors and other diseases.